



Crohn's/Ulcerative Colitis Enrollment Form

Phone: 855-425-4085

Fax: 855-425-4096

ardonhealth.com

<b>PATIENT INFORMATION</b>	Patient Name: _____	<b>PRESCRIBER INFORMATION</b>	Prescriber's Name: _____
	Address: _____		State License #: _____ NPI #: _____
	City: _____ State: _____ Zip: _____		DEA #: _____
	Primary Phone: _____ DOB: _____		Group or Hospital: _____
	Alternate Phone: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female		Address: _____
	Email: _____		City: _____ State: _____ Zip: _____
	Primary Language: _____		Phone: _____ Fax: _____
	Height: _____ Weight: _____		Contact Person: _____ Phone: _____

**INSURANCE INFORMATION:** PLEASE FAX A COPY OF THE PRESCRIPTION & INSURANCE CARDS WITH THIS FORM, IF AVAILABLE (FRONT & BACK)

<b>CLINICAL</b>	<b>Need By Date:</b> _____	<b>Ship to:</b> <input type="checkbox"/> Patient <input type="checkbox"/> Physician <input type="checkbox"/> Other:
	<b>Date of Diagnosis:</b> _____	<b>Diagnosis ICD-10 Code:</b> Crohn's Disease <input type="checkbox"/> K50.90 Ulcerative Colitis <input type="checkbox"/> K51.90 Other (ICD-10 Code) <input type="checkbox"/> _____
	<b>Previous Medications:</b> _____	
	<b>Current Medications:</b> _____	
	<b>Allergies:</b> _____ <b>Latex Allergy?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No	
	<b>Does patient have Active/Serious Infection?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No <b>Does patient have Heart Failure?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No	
	<b>Has patient had a positive TB test?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No If Yes, Date of last Chest X-Ray: _____ <b>Is the patient new to therapy?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No	

MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILL
<input type="checkbox"/> Cimzia®	<input type="checkbox"/> Starter Kit <input type="checkbox"/> 200 mg/mL Prefilled Syringe <input type="checkbox"/> 200 mg Vial	<input type="checkbox"/> Induction Dose: Inject 400 mg SUBQ on day 1, 15, and 29 <input type="checkbox"/> Maintenance Dose: Inject 400 mg SUBQ every 28 days	<input type="checkbox"/> 1 Starter Kit = 6 PFS <input type="checkbox"/> 2 PFS/Vials	0
<input type="checkbox"/> Humira® (Citrate-free)	<b>Starter Dose</b> <input type="checkbox"/> 80 mg/0.8 mL Pen Crohn's Disease, Ulcerative Colitis Starter (3 pens) <input type="checkbox"/> 40 mg/0.4 mL Pen Crohn's Disease, Ulcerative Colitis Starter (6 pens) <input type="checkbox"/> 80 mg/0.8 mL Prefilled Syringe Pediatric Crohn's Disease Starter (3 syringes) <input type="checkbox"/> 80 mg/0.8 mL and 40 mg/0.4 mL Prefilled Syringe Pediatric Crohn's Disease Starter (2 syringes) <input type="checkbox"/> 80 mg/0.8 mL Pen Pediatric Ulcerative Colitis Starter (4 pens) <input type="checkbox"/> 40 mg/0.4 mL Pen Pediatric Ulcerative Colitis (4 pens) <input type="checkbox"/> 40 mg/0.4 mL Prefilled Syringe Pediatric Ulcerative Colitis (4 syringes)	<input type="checkbox"/> Adult Crohn's/UC and pediatric Crohn's ≥ 40 kg: Inject 160 mg SUBQ on day 1, 80 mg on day 15, then 40 mg every 14 days thereafter starting on day 29 <input type="checkbox"/> Pediatric Crohn's 17 to < 40 kg: Inject 80 mg SUBQ on day 1, 40 mg on day 15, then 20 mg every 14 days starting on day 29 <input type="checkbox"/> Pediatric UC ≥ 40 kg: Inject 160 mg SUBQ on day 1, 80 mg on day 8, 80 mg on day 15, then begin maintenance dosing starting on day 29 <input type="checkbox"/> Pediatric UC 20 kg to < 40 kg: Inject 80 mg SUBQ on day 1, 40 mg on day 8, 40 mg on day 15, then begin maintenance dosing starting on day 29 <input type="checkbox"/> Other: _____	<input type="checkbox"/> 1 Kit	0
	<b>Maintenance Dose</b> <input type="checkbox"/> 80 mg/0.8 mL CF Pen <input type="checkbox"/> 40 mg/0.4 mL CF Pen <input type="checkbox"/> 40 mg/0.4 mL CF Prefilled Syringe <input type="checkbox"/> 20 mg/0.2 mL CF Prefilled Syringe <input type="checkbox"/> 10 mg/0.1 mL CF Prefilled Syringe	<input type="checkbox"/> Inject 40 mg SUBQ every 14 days <input type="checkbox"/> Inject 80 mg SUBQ every 14 days <input type="checkbox"/> Inject 40 mg SQ every 7 days <input type="checkbox"/> Other: _____	<input type="checkbox"/> 2 Pens/PFS <input type="checkbox"/> 4 Pens/PFS	_____

X
X
  
**PHYSICIAN SIGNATURE REQUIRED**
  
 \_\_\_\_\_ (Date) \_\_\_\_\_ (Date)
   
 PRODUCT SUBSTITUTION PERMITTED (Date) DISPENSE AS WRITTEN (Date)
   
 Ancillary supplies and kits will be provided as needed for administration.

Date Needed: \_\_\_\_\_ Medication Start Date: \_\_\_\_\_

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 0125 (11/22)



MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILL
<input type="checkbox"/> Humira®	<input type="checkbox"/> 40 mg/0.8 mL Pen Crohn's Disease, Ulcerative Colitis Starter (6 pens) <input type="checkbox"/> 40 mg/0.8 mL Prefilled Syringe Pediatric Crohn's Disease Starter (6 syringes) <input type="checkbox"/> 40 mg/0.8 mL Prefilled Syringe Pediatric Crohn's Disease Starter (3 syringes)	<input type="checkbox"/> Adult Crohn's/UC and pediatric Crohn's ≥ 40 kg: Inject 160 mg SUBQ on day 1, 80 mg on day 15, then 40 mg every 14 days thereafter starting on day 29 <input type="checkbox"/> Pediatric Crohn's 17 to < 40 kg: Inject 80 mg SUBQ on day 1, 40 mg on day 15, then 20 mg every 14 days starting on day 29 <input type="checkbox"/> Other: _____	<input type="checkbox"/> 1 Kit	0
	<input type="checkbox"/> 40 mg/0.8 mL Pen <input type="checkbox"/> 40 mg/0.8 mL Prefilled Syringe <input type="checkbox"/> 20 mg/0.4 mL Prefilled Syringe <input type="checkbox"/> 10 mg/0.2 mL Prefilled Syringe	<input type="checkbox"/> Inject 40 mg SUBQ every 14 days <input type="checkbox"/> Inject 40 mg SUBQ every 7 days <input type="checkbox"/> Other: _____	<input type="checkbox"/> 2 Pens/PFS <input type="checkbox"/> 4 Pens/PFS	_____
<input type="checkbox"/> Remicade®	<input type="checkbox"/> 100 mg Vial	<input type="checkbox"/> Induction: Infuse _____ mg IV at weeks 0, 2, and 6	_____ Vial(s)	0
		<input type="checkbox"/> Maintenance: Infuse _____ mg IV every 8 weeks	_____ Vial(s)	_____
<input type="checkbox"/> Rinvoq®	<input type="checkbox"/> 45 mg XR Tablet	<input type="checkbox"/> Take 1 tablet by mouth once daily	<input type="checkbox"/> 28 Tablets	_____
	<input type="checkbox"/> 15 mg XR Tablet <input type="checkbox"/> 30 mg XR Tablet	<input type="checkbox"/> Take 1 tablet by mouth once daily	<input type="checkbox"/> 30 Tablets	_____
<input type="checkbox"/> Simponi®	<input type="checkbox"/> 100 mg/mL Pen <input type="checkbox"/> 100 mg/mL Prefilled Syringe	<input type="checkbox"/> Induction Dose: Inject 200 mg SUBQ day 1, then 100 mg on day 15, then 100 mg every 28 days thereafter	<input type="checkbox"/> 3 Pens/PFS	0
		<input type="checkbox"/> Maintenance Dose: Inject 100 mg SUBQ every 28 days	<input type="checkbox"/> 1 Pen/PFS	_____
<input type="checkbox"/> Skyrizi®	<input type="checkbox"/> 180 mg/1.2 mL prefilled cartridge with on-body injector	<input type="checkbox"/> Maintenance Dose: Inject 180 mg SUBQ at week 12, followed by every 8 weeks thereafter <input type="checkbox"/> Maintenance Dose: Inject 360 mg SUBQ at week 12, followed by every 8 weeks thereafter Has the patient received the IV induction doses already? <input type="checkbox"/> Yes <input type="checkbox"/> No If Yes, date of IV induction doses: Week 0: _____ Week 4: _____ Week 8: _____	<input type="checkbox"/> 1 Kit	_____
	<input type="checkbox"/> 360 mg/2.4 mL prefilled cartridge with on-body injector			_____
<input type="checkbox"/> Stelara®	<input type="checkbox"/> 90 mg Prefilled Syringe	<input type="checkbox"/> Maintenance Dose: Inject 90 mg SUBQ 8 weeks after initial IV dose, followed by every 8 weeks thereafter Has the patient received the IV induction dose already? <input type="checkbox"/> Yes <input type="checkbox"/> No If Yes, date of IV induction dose: _____	<input type="checkbox"/> 1 PFS	_____
<input type="checkbox"/> Xeljanz®	<input type="checkbox"/> 10 mg Tablet	<input type="checkbox"/> Take 1 tablet by mouth 2 times daily	<input type="checkbox"/> 60 Tablets	_____
	<input type="checkbox"/> 5 mg Tablet	<input type="checkbox"/> Take 1 tablet by mouth 2 times daily	<input type="checkbox"/> 60 Tablets	_____
		<input type="checkbox"/> Other: _____	_____	_____
	<input type="checkbox"/> 22 mg XR Tablet <input type="checkbox"/> 11 mg XR Tablet	<input type="checkbox"/> Take 1 tablet by mouth once daily	<input type="checkbox"/> 30 Tablets <input type="checkbox"/> 30 Tablets	_____ _____
<input type="checkbox"/> Zeposia	<input type="checkbox"/> Titration Pack (7-day) <input type="checkbox"/> Titration Pack (37-day)	<input type="checkbox"/> Titration Dose: 0.23 mg by mouth once daily on day 1-4, 0.46 mg once daily on day 5-7, followed by 0.92 mg once daily thereafter	<input type="checkbox"/> 1 Titration Kit	NA
	<input type="checkbox"/> 0.92mg Capsule	<input type="checkbox"/> Take 1 tablet by mouth daily	<input type="checkbox"/> 30 Tablets	_____

PRESCRIPTION INFORMATION

X
X
  
**PHYSICIAN SIGNATURE REQUIRED**
  
 \_\_\_\_\_ (Date) \_\_\_\_\_ (Date)

PRODUCT SUBSTITUTION PERMITTED (Date) DISPENSE AS WRITTEN (Date)

Ancillary supplies and kits will be provided as needed for administration.

Date Needed: \_\_\_\_\_ Medication Start Date: \_\_\_\_\_

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 0125 (11/22)

This prescription is valid only if transmitted by facsimile machine by a licensed provider.